Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Opat

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Leukemia|March 31, 2025
Zanubrutinib in Bing Neel syndrome: efficacy and tolerabilityAnne-Marie L Becking, Johannes P M van de Mortel, Oliver Tomkins, et al.
The New England Journal of Medicine|January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsValentin Goede, Kirsten Fischer, Raymonde Busch, et al.
Hematological Oncology|April 16, 2019
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphomaZi Yun Ng, Mark Bishton, David Ritchie, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
Internal Medicine Journal|July 25, 2022
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer CentreConstantine S Tam, Gareth P Gregory, Matthew Ku, et al.
NEJM Evidence|June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's LymphomaAngie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Blood Advances|September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA studyStephen Opat, Alessandra Tedeschi, Bei Hu, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Leukemia|March 31, 2025
Zanubrutinib in Bing Neel syndrome: efficacy and tolerabilityAnne-Marie L Becking, Johannes P M van de Mortel, Oliver Tomkins, et al.
The New England Journal of Medicine|January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsValentin Goede, Kirsten Fischer, Raymonde Busch, et al.
Hematological Oncology|April 16, 2019
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphomaZi Yun Ng, Mark Bishton, David Ritchie, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
Internal Medicine Journal|July 25, 2022
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer CentreConstantine S Tam, Gareth P Gregory, Matthew Ku, et al.
NEJM Evidence|June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's LymphomaAngie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Blood Advances|September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA studyStephen Opat, Alessandra Tedeschi, Bei Hu, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Pageof 13